SOM Biotech Competitors and Similar CompaniesClear all
BenevolentAI's competitors and similar companies include Geneos Therapeutics and Keros Therapeutics.
 BenevolentAI BenevolentAI is a company that develops artificial intelligence and machine learning technologies for drug discovery and life sciences. |  Geneos Therapeutics Geneos Therapeutics is a biotherapeutics company that develops DNA-based personalized therapeutic cancer vaccines. |  Keros Therapeutics Keros Therapeutics is a biotechnology company that develops therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta. | |
Founding Date | Founding Date 2013 | Founding Date N/A | Founding Date 2015 |
Type | Type Private | Type Private | Type Public |
Tags | |||
Locations | Locations London, GB HQ Babraham, GB | Locations Plymouth Meeting, US HQ | Locations Lexington, US HQ South Wharf, AU |
Employees | Employees 180 | Employees 128% decrease | Employees 7854% decrease |
Valuation ($) | Valuation ($) 1 b | Valuation ($) N/A | Valuation ($) 2.3 b |
Financial | |||
Revenue (est.) | Revenue (est.) €7.3m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $244.1m (FY, 2025) |
Net income | Net income (€63.3m) (FY, 2023) | Net income N/A | Net income $87m (FY, 2025) |
Funding | |||
Latest funding round | Latest funding round $ 90m (almost 7 years ago) | Latest funding round $ 12m (over 5 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 305m | Total funding raised $ 22.5m | Total funding raised $ 90m |
For sources of this data, please see the company profile
View Company Profiles
Geneos Therapeutics
HQ
Plymouth Meeting, US
Employees
12↓ 8% decrease
Geneos Therapeutics is a biotherapeutics company that develops DNA-based personalized therapeutic cancer vaccines.
View companyKeros Therapeutics
HQ
Lexington, US
Employees
78
Keros Therapeutics is a biotechnology company that develops therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta.
View company